SCHEMBL6587705

SCHEMBL6587705

COc1cc2cnnc(Nc3c(Cl)cncc3Cl)c2cc1OC1CCCC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 13/20 0.67
PDE4A P27815 8/20 0.67
PDE4C Q08493 8/20 0.67
PDE4D Q08499 8/20 0.67
FLT1 P17948 1/20 0.47
EGFR P00533 1/20 0.47
EPHA2 P29317 1/20 0.46
KDR P35968 1/20 0.46
EPHB4 P54760 1/20 0.46
SOS1 Q07889 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ABL1 P00519 1/20 0.38
SRC P12931 1/20 0.38
ABL2 P42684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6587544 0.80 PDE4D (1.00) PDE4BPDE4APDE4CPDE4D
SCHEMBL6586279 0.79 PDE4B (1.00) PDE4BPDE4APDE4CPDE4D
SCHEMBL7380336 0.75 PDE4B (0.64) PDE4BPDE4APDE4CPDE4DEPHA2
SCHEMBL6584614 0.70 PDE4D (1.00) PDE4BPDE4APDE4CPDE4D
SCHEMBL13624574 0.69 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DEPHA2
SCHEMBL6586199 0.69 PDE4D (1.00) PDE4BPDE4APDE4CPDE4D
SCHEMBL4364962 0.69 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DEGFR
SCHEMBL72555 0.68 PDE4D (0.73) PDE4BPDE4APDE4CPDE4D
SCHEMBL4361797 0.68 PDE4B (0.74) PDE4BPDE4APDE4CPDE4D
SCHEMBL71427 0.67 PDE4B (0.66) PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043999-A1 Phthalazine derivatives as phosphodiesterase 4-inhibitors ZAMBON GROUP S.P.A 2004-03-04 US disclosed
EP-1042300-B1 PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON SPA (IT) 2004-02-11 EP disclosed
US-6589951-B1 N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. ZAMBON GROUP S.P.A. (IT) 2003-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043999-A1 Phthalazine derivatives as phosphodiesterase 4-inhibitors PDE5A, PDE3B, PDE3A PDE4B 9/4885PDE4A 7/4885PDE4C 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.